Oral News and Research

RSS

iPrEx update, bone mineral density study highlighted at day three of 18th CROI

The 18th Conference on Retroviruses and Opportunistic Infections is being held at the Hynes Convention Center in Boston from February 27 through March 2. Day three of this major HIV/AIDS research conference included the following selected presentations from scientists supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

5 Mar 2011

Smile Brands announces grand opening of its new Castle Dental office in Houston

Smile Brands Inc., the nation's leading provider of business support services to dental groups in the United States, today announced the grand opening of its newest Castle Dental office in Houston – the 36th office in the Houston area.

5 Mar 2011

Brands announces grand opening of its new Bright Now Dental office in Fountain Valley

Brands Inc., the nation's leading provider of business support services to dental groups in the United States, today announced the grand opening of its newest Bright Now Dental office in Fountain Valley – the 50th office in Southern California. Bright Now Dental will continue its growth pattern in Southern California over the next two years, with offices slated to open in Escondido, Simi Valley, El Cajon, and Upland later this year and further expansion in 2012.

5 Mar 2011

Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints

Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.

5 Mar 2011

Study: BMP can improve dental implant success

Using a bone-creating protein to augment the maxillary sinus could improve dental implant success, according to Georgia Health Sciences University researchers.

5 Mar 2011

IMMY, University of Nevada, Reno collaborate to make new blood test for Cryptococcosis

A new, rapid blood test that could lead to early diagnosis and potentially save the lives of hundreds of thousands of people stricken with fungal meningitis, a leading cause of AIDS-related deaths in developing countries, is getting closer to market with a recent collaboration between the University of Nevada, Reno and Immuno-Mycologics in Oklahoma.

5 Mar 2011

Topamax medication during pregnancy can lead to increased risk of oral birth defects in babies

New data suggest that the drug Topamax and its generic versions increase the risk for the birth defects cleft lip and cleft palate in babies born to women who use the medication during pregnancy, the U.S. Food and Drug Administration said today.

5 Mar 2011

Sangamo's preclinical ZFN-gene modification studies for HIV/AIDS treatment presented at CROI

Sangamo BioSciences, Inc. announced that data from its programs to develop ZFN-based therapeutic approaches for the treatment of HIV/AIDS were discussed in four oral presentations at the 18th Conference on Retroviruses and Opportunistic Infections, held in Boston from February 27 to March 2, 2011.

4 Mar 2011

CT scanning offers benefit to patients undergoing dental implant surgery

Computerized tomography has proved a useful tool in reconstructive dental implant surgery where a bone graft is required. It provides reliable information in diagnosis and treatment planning and has been used to determine the volume of bone for grafts.

4 Mar 2011

Eisai receives FDA approval for BANZEL Oral Suspension to treat seizures linked with LGS

Eisai Inc. today announced that the U.S. Food and Drug Administration has approved BANZEL Oral Suspension, 40 mg/mL, for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults.

3 Mar 2011

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Infinity Pharmaceuticals, Inc. today announced the initiation of a randomized, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of IPI-926 compared to placebo in patients with metastatic or locally advanced, inoperable chondrosarcoma. The trial is expected to enroll over 100 patients worldwide.

3 Mar 2011

Roche, OraSure receive FDA 510(k) clearance for Oral Fluid Drug Testing System

OraSure Technologies, Inc. and Roche announced today that the U.S. Food and Drug Administration has granted the Companies 510(k) clearance on four homogeneous fully automated oral fluid drugs of abuse assays developed to be used exclusively as part of OraSure's Intercept Oral Fluid Drug Testing System.

3 Mar 2011

FDA takes action against companies that manufacture unapproved prescription drugs

The U.S. Food and Drug Administration today took action against companies that manufacture, distribute, or market certain unapproved prescription oral cough, cold, and allergy products. The affected products cannot be legally marketed in the United States.

3 Mar 2011

Alternative intraoral appliance to treat obstructive sleep apnea

AZ-TMJ is once again leading the way in innovative and effective treatments for patients with obstructive sleep apnea (OSA). Approximately one in five adults have at least mild sleep apnea, and one in 15 are classified as moderate sleep apnea sufferers. Sleep apnea is a disorder where a person's ability to breathe is impaired, resulting in a restless sleep and oftentimes snoring.

3 Mar 2011

Scientists devise new on-line calculator to predict food allergies in children

An on-line calculator that predicts, within seconds, the presence of the three major food allergies in children has been developed by researchers at University College Cork.

2 Mar 2011

Calypte Biomedical completes new Aware HIV-1/2 oral fluid rapid test internal studies

Calypte Biomedical Corporation, a developer, manufacturer and marketer of HIV diagnostic tests, today announced successful completion of internal studies of its new Aware HIV-1/2 oral fluid rapid test for the US and international markets.

2 Mar 2011

Virostatics' VS411 Phase 2a trial results against HIV presented at 18th CROI

An analysis of immune markers measured in a sub-study of ViroStatics' proof-of-concept Phase 2a trial showed that VS411 was able to reduce immune activation while producing a median 1.5 log10 reduction in viral load.

2 Mar 2011

Court case question: Who holds the patent — drug company or research institution

The invention of an AIDS test is a big deal, and it takes a lot of time, smarts and money to develop a good one. So there's a lot at stake in the legal tussle between Stanford University and the pharmaceutical giant Roche, with oral arguments opening Monday before the U.S. Supreme Court.

2 Mar 2011

EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) on the new drug application (NDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing-remitting multiple sclerosis (MS).

2 Mar 2011

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.

2 Mar 2011

Oral News and Research

iPrEx update, bone mineral density study highlighted at day three of 18th CROI

Smile Brands announces grand opening of its new Castle Dental office in Houston

Brands announces grand opening of its new Bright Now Dental office in Fountain Valley

Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints

Study: BMP can improve dental implant success

IMMY, University of Nevada, Reno collaborate to make new blood test for Cryptococcosis

Topamax medication during pregnancy can lead to increased risk of oral birth defects in babies

Sangamo's preclinical ZFN-gene modification studies for HIV/AIDS treatment presented at CROI

CT scanning offers benefit to patients undergoing dental implant surgery

Eisai receives FDA approval for BANZEL Oral Suspension to treat seizures linked with LGS

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Roche, OraSure receive FDA 510(k) clearance for Oral Fluid Drug Testing System

FDA takes action against companies that manufacture unapproved prescription drugs

Alternative intraoral appliance to treat obstructive sleep apnea

Scientists devise new on-line calculator to predict food allergies in children

Calypte Biomedical completes new Aware HIV-1/2 oral fluid rapid test internal studies

Virostatics' VS411 Phase 2a trial results against HIV presented at 18th CROI

Court case question: Who holds the patent — drug company or research institution

EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News